|
| Study | Phenotypic analysis of CIK cells | Cytotoxicity assays |
|
| Schmidt-Wolf et al. [37] | — | Cytotoxic activity of PBMC against HLA-matched carcinoma cell lines and K562 cells increased during treatment |
| Ren et al. [31] | Significant increase in CD3+, CD4+, CD8+, CD25+, and CD3+CD56+ cells after 14–16 days of culture | Cytotoxicity of PBMC against K562 cells after multicycles of CIK cell infusions significantly increased |
| Olioso et al. [38] | After 21 days of culture, CD3+ cells expanded 34-fold and CD3+CD56+ 270-fold; increases in CD3+, CD8+, and CD3+CD56+ cells in circulating lymphocytes seven days after CIK cell infusion | Cytotoxicity of CIK cells from RCC patients tested against 293 cells: at an E/T of 20 : 1, the median percentage lysis was 45%; at an E/T of 40 : 1, 54% were lysed |
| Su et al. [40] | After 14 days of culture, increases in CD3+, CD4+, CD8+, CD+CD56+ and NKG2D+ cells were detected while the number of CD4+CD25+CD127 low+ (Treg) cells decreased; the same changes were detected in PBMC after CIK therapy | Cytotoxicity of CIK cells tested against K562 cells (E/T ratio of 60 : 1): the median toxicity was
77, 2%; cytotoxicity of CIK cells tested against RCC cells (E/T ratio of 60 : 1): CIK cells lysed 50,4% of 293 cells and 32,1% of SK-RC-42 cells |
| Liu et al. [13] | — | Cytotoxicity of CIK cells tested against RCC cells (E/T ratio of 50 : 1): CIK cells lysed 35,41% of 786-O cells and 32,17% of SK-RC-42 cells |
| Wang et al. [43] | After treatment for two months, levels of CD3+, CD4+, CD4+CD8+, and CD56+ increased significantly | — |
|
